Prostatic Neoplasms (Prostate Cancer)

Subscribe to Selected New Research on Prostatic Neoplasms

27261 relevant articles (1551 outcomes, 5308 trials/studies) found for this Disease

Description: Tumors or cancer of the PROSTATE.

Also Known As:

Prostate Cancer; Cancer of the Prostate; Neoplasms, Prostate; Neoplasms, Prostatic; Prostate Neoplasms; Prostatic Cancer; Cancer, Prostate; Cancer, Prostatic; Cancers, Prostate; Cancers, Prostatic; Neoplasm, Prostate; Neoplasm, Prostatic; Prostate Cancers; Prostate Neoplasm; Prostatic Cancers; Prostatic Neoplasm; Cancer of Prostate

Relationship Network

Disease Context: Research Results

Neoplasms: 387640

Neoplasms by Site: 1

Urogenital Neoplasms: 169

Male Genital Neoplasms

Prostatic Neoplasms: 27261

Male Urogenital Diseases

Urogenital Neoplasms: 169

Male Genital Neoplasms

Prostatic Neoplasms: 27261

Male Genital Diseases

Prostatic Diseases: 299

Prostatic Neoplasms: 27261

Male Genital Neoplasms

Prostatic Neoplasms: 27261

Related Diseases

1.	Neoplasms (Cancer)
2.	Neoplasm Metastasis (Metastasis)
3.	Pain (Aches)
4.	Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
5.	Breast Neoplasms (Breast Cancer)

Experts

1.	Small, Eric J: 65 articles (09/2008 - 02/2002)
2.	Thompson, Ian M: 54 articles (10/2008 - 11/2002)
3.	Partin, Alan W: 51 articles (12/2008 - 01/2002)
4.	Kantoff, Philip W: 47 articles (09/2008 - 01/2002)
5.	Beer, Tomasz M: 41 articles (09/2008 - 01/2002)
6.	D'Amico, Anthony V: 41 articles (05/2008 - 05/2002)
7.	Scher, Howard I: 40 articles (10/2008 - 01/2002)
8.	Oh, William K: 39 articles (10/2008 - 02/2002)
9.	Klein, Eric A: 39 articles (06/2008 - 01/2002)
10.	Sarkar, Fazlul H: 37 articles (12/2008 - 06/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Prostatic Neoplasms:

1.	HormonesIBA 07/01/2008 - "Our understanding of the biology of hormone refractory prostate cancer has improved dramatically over the past few years and has translated into the developments of new therapeutic targets for this disease" 10/15/2006 - "Despite the initial efficacy of androgen deprivation therapy, most patients with advanced prostate cancer eventually progress to hormone-refractory prostate cancer, for which there is no curative therapy" 08/01/2006 - "There is no effective cure for late-stage hormone (androgen) refractory prostate cancer" 12/01/1984 - "In some clinical trials the use of criteria of stable response of hormone-escaped prostate cancer is justified on the ground that it delineates patients with markedly improved survival, similar to that of partial regression patients" 09/01/2008 - "A considerable proportion of men with clinically localized prostate cancer are not cured by surgery or radiotherapy, and hormone therapy for advanced disease is also not curative" Order ALL the reference details at left...
2.	Prostate-Specific Antigen (Semenogelase)IBA 02/01/2008 - "The prostate-specific antigen value and the percent positive biopsy cores can be helpful in identifying men with high-grade prostate cancer most likely to benefit from RP" 01/01/2004 - "The use of total prostate-specific antigen (tPSA) measurement has dramatically improved the ability to detect prostate cancer at earlier stages" 01/01/2001 - "Prostate-specific antigen (PSA) has been extremely helpful in the detection of new or recurrent prostate cancer" 12/01/2003 - "OBJECTIVE: To report the initial results from Sweden of a large population-based randomized study of screening using prostate-specific antigen (PSA) to detect prostate cancer, as the efficacy of such screening to decrease prostate cancer mortality has not yet been proven" 01/01/1999 - "The detection and treatment of prostate cancer has been markedly improved by the use of Prostate-Specific Antigen (PSA) as a serological biomarker for disease" Order ALL the reference details at left...
3.	docetaxel (Taxotere)FDA Link 11/01/2007 - "One of the major obstacles in curing prostate cancer is the development of drug resistance to docetaxel, which is the gold standard for the treatment of this disease" 09/01/2007 - "Recently, docetaxel has been added to standard androgen ablation as an effective treatment for advanced prostate cancer." 01/15/2004 - "Taxotere is a cytotoxin effective in treating breast and prostate cancer" 05/01/2006 - "Docetaxel has been shown to improve survival in patients with metastatic prostate cancer" 08/01/2008 - "The most relevant studies involving patients with prostate cancer receiving therapy with docetaxel, alone or in combination with other agents, have been summarised" Order ALL the reference details at left...
4.	Gonadotropin-Releasing Hormone (GnRH)FDA Link 07/01/2004 - "The diagnosis and treatment of prostate cancer have been dramatically improved due to the development of PSA screening, transrectal ultrasonography and new anti-androgen drugs, such as LH-RH analog, with fewer side effects" 01/01/2007 - "ABSTRACT: BACKGROUND: Oncological results of radiotherapy for locally advanced prostate cancer (PC) are significantly improved by simultaneous application of LHRH analoga (e.g" 05/01/1987 - "In view of their effectiveness and good tolerance, LHRH agonists are useful in the management of advanced prostatic cancer, either as initial therapy or to replace a poorly tolerated oestrogen therapy" 05/01/2008 - "Gonadotropin-releasing hormone (GnRH) agonists are the mainstay of treatment for recurrent and metastatic prostate cancer" 09/22/2005 - "Are all LH-RH analogues equally effective in prostate cancer?]" Order ALL the reference details at left...
5.	Estramustine FDA Link 01/01/1996 - "CONCLUSIONS: With now over 10 years mean follow-up for this series of patients, we conclude that adjuvant estramustine is beneficial for prostate cancer patients receiving definitive irradiation" 02/01/1993 - "Adjuvant estramustine phosphate was beneficial in patients with prostate cancer and pelvic node involvement who received irradiation as definitive treatment." 03/01/1984 - "Estracyt Research Group in Japan concluded that Estracyt was effective in 38% of reactivated prostatic cancer patients (15% (I-C, I-B), 23% (I-A, O-B, O-C]" 05/01/1988 - "Stage D1 prostatic cancer benefited by a single regimen of Estracyt]" 01/31/1982 - "Total remission of prostatic cancer following treatment with Estracyt]" Order ALL the reference details at left...
6.	Flutamide (Eulexin)FDA LinkGeneric 09/01/2000 - "Parameters of liver function, serum GOT and GPT levels, which were normal at the baseline, became abnormal in 30.0% and 35.3%, respectively, of patients in Group II. These figures were significantly higher than the corresponding figures of 6.3% and 12.5%, respectively, in Group I. When the degree of change in each of these parameters was analyzed, both GOT and GPT levels showed a significantly greater increase in Group II than in Group I. CONCLUSION: These results indicate that attention must be paid to changes in liver function during the administration of flutamide in patients with prostate cancer even if their baseline liver function is normal" 06/01/1986 - "Since uninterrupted administration of the antiandrogen is of the outmost importance for the successful therapy of prostatic cancer, the availability of a compound such as flutamide that has no side effect other than those due to hypoandrogenicity should greatly facilitate compliance by the patients and the success of the treatment." 11/01/2003 - "CONCLUSIONS: The administration of low-dose flutamide (125 mg) was clinically effective in treating PSA recurrence after definitive treatments for prostate cancer, and was well tolerated" 01/01/1990 - "Our preliminary experience shows that flutamide is effective in patients with stage C or D prostate cancer" 01/01/1989 - "The foregoing findings demonstrate that flutamide monotherapy is an effective treatment for prostatic cancer and can be chosen for younger patients who wish to conserve their sexual potency." Order ALL the reference details at left...
7.	Testosterone (Sustanon)FDA LinkGeneric 01/01/2003 - "Long-term use of these patches over the last 3 to 10 years has been effective in maintaining sexual function and bone and muscle mass, and from short-term studies it does not appear that testosterone treatment puts men at risk for the development of prostate cancer" 02/01/2005 - "Testosterone-BSA was also effective in inducing apoptosis of DU145 human prostate cancer cells, negative for iAR, but expressing mAR sites" 05/01/2003 - "Combination androgen blockade or non-steroidal anti-androgen agent appears to be effective for the treatment of prostatic cancer patients who takes exogenous androgenic medicine, even with a suppressed low serum testosterone level." 06/01/2002 - "In patients with prostate cancer, serum testosterone levels are reduced to castrate levels (< or = 50 ng/dl) within 2-3 weeks of the first one-month depot injection of 3.75 mg or three-month depot injection of 11.25 mg. Both the one-month and three-month formulations are effective in delaying tumour progression and alleviating symptoms of locally advanced and metastatic prostate cancer" 01/01/1988 - "Early work showed these agents to be an effective treatment of prostatic cancer, establishing an intranasal dosage regimen that suppressed serum testosterone into the castrate range" Order ALL the reference details at left...
8.	zoledronic acid (zoledronate)FDA Link 03/01/2007 - "CONCLUSION: Zoledronic acid (4 mg intravenously every 3 months) was safe and effective in preventing bone loss and reducing bone turnover in patients with prostate cancer when initiated during the first year of androgen deprivation therapy; patients with low baseline BMD experienced the greatest benefit." 10/01/2002 - "The objective of this study was to evaluate the efficacy of zoledronate in limiting the formation and/or progression of osteoblastic lesions produced by the injection of known prostate cancer cells (LAPC-9 and PC-3 cells) into the tibia of SCID mice" 05/01/2008 - "MATERIALS AND METHODS: A nationwide, observational, prospective, open and multi-centre trial was devised, with a total of 218 male patients diagnosed with prostate cancer at the HS stage (36%) or HI stage (64%) who were administered zoledronic acid (4 mg/IV/month for 6 months) in addition to their specific oncological treatment" 03/01/2007 - "PURPOSE: The aim of this study was to evaluate the efficacy and safety of zoledronic acid compared with placebo in preventing bone mineral density (BMD) loss and suppressing bone markers when initiated during the first year of androgen deprivation therapy in patients with locally advanced prostate cancer" 01/01/2005 - "The therapeutic potential of zoledronic acid for the treatment of prostate cancer has been demonstrated in both preclinical and clinical studies" Order ALL the reference details at left...
9.	bicalutamide (Casodex)FDA Link 02/01/2006 - "Bicalutamide significantly improved overall survival in patients receiving radiotherapy (HR 0.65; 95% CI 0.44-0.95; P = 0.03); this was driven by a lower risk of prostate cancer-related deaths" 07/01/2005 - "CONCLUSIONS: Bicalutamide 150 mg/day given as adjuvant to radiotherapy significantly improved PFS in patients with locally advanced prostate cancer" 01/01/1989 - "Following promising results in animal studies, Casodex (ICI 176,334) has been studied in the treatment of patients with advanced prostate cancer" 04/01/2005 - "Compared to bicalutamide, YM-175735 is an approximately 4-fold stronger AR antagonist and has slightly increased antiandrogenic activity, suggesting that YM-175735 may be useful in the treatment of prostate cancer." 11/01/2002 - "OBJECTIVES: To compare the efficacy of bicalutamide monotherapy to maximal androgen blockade in advanced prostatic cancer" Order ALL the reference details at left...
10.	Biological Markers (Surrogate Marker)IBA 01/18/2008 - "Future studies on the identified differentially expressed genes and signaling pathways may be helpful in understanding the biology of prostate cancer progression and prove useful in developing novel prognostic biomarkers and therapy for androgen-refractory prostate cancer." 06/01/2006 - "Prostate cancer has been a focus of many such studies with the promise of improved care to patients via biomarkers derived from these proteomic approaches" 11/01/2004 - "Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer." 07/01/2004 - "There is a need for improved biomarkers for detecting prostate cancer" 06/02/2004 - "Improved biomarkers for prostate cancer: a definite need." Order ALL the reference details at left...

Therapies and Procedures

1.	Prostatectomy (Retropubic Prostatectomy) 11/01/2008 - "OBJECTIVES: To quantify the relative improvement in prostate cancer-specific survival of salvage radiotherapy vs. no therapy after biochemical recurrence following prostatectomy, and to identify subgroups for whom salvage treatment is most beneficial" 06/18/2008 - "OBJECTIVES: To quantify the relative improvement in prostate cancer-specific survival of salvage radiotherapy vs no therapy after biochemical recurrence following prostatectomy, and to identify subgroups for whom salvage treatment is most beneficial" 07/01/2007 - "OBJECTIVE: Radical prostatectomy is the most effective treatment for localized prostate cancer" 06/01/2007 - "While most currently diagnosed prostate cancers are localized, radical prostatectomy remains a gold standard treatment" 02/01/2007 - "Radical prostatectomy is the most effective treatment for localized prostate cancer" Order ALL the reference details at left...
2.	Drug Therapy (Chemotherapy) 08/01/2004 - "Androgen ablation and chemotherapy provide effective palliation for most patients with advanced prostate cancer, but eventually progressing androgen-independent prostate cancer threatens the lives of patients usually within a few years, mandating improvement in therapy" 01/01/2004 - "Although some anticancer efficacy of signal transduction inhibition monotherapy was reported, combination with chemotherapy and radiotherapy seemed most promising in prostate cancer" 11/01/2007 - "CONCLUSIONS: Vinexinbeta plays an important role in PC-3 cell growth, and abrogation of vinexinbeta may be effective for therapeutic cell death and enhanced chemotherapy sensitization in androgen-independent prostate cancer cells." 06/01/2002 - "While chemotherapy has proven efficacy when the disease progresses to androgen-independent prostate cancer, patients ultimately succumb to the disease, thus the identification of other active therapies is needed" 04/24/2007 - "The inhibitor induces apoptosis and inhibits the phosphorylation of PKB substrates in prostate cancer cell lines and significantly increases the efficacy of chemotherapy agents to induce prostate cancer cell death, when given in combination" Order ALL the reference details at left...
3.	Brachytherapy 04/01/2006 - "Permanent prostate brachytherapy with or without supplemental therapies is a highly effective treatment for clinically localized prostate cancer, with biochemical outcomes and morbidity profiles comparing favorably with competing local modalities" 10/01/2004 - "Early treatment of prostate cancer has benefited from important advances in surgical and radio-therapeutic techniques (conformational irradiation, brachytherapy), with, as principal goal, the combination of a better survival and the reduction of the potential adverse effects that alter quality of life" 09/01/2002 - "CONCLUSION: We have had very good results during the first twenty one months of treatment of cancer of the prostate with brachytherapy" 06/01/2002 - "CONCLUSION: Pelvic EBRT interdigitated with transrectal ultrasound-guided real-time conformal HDR prostate brachytherapy boost is both a precise dose delivery system and a very effective treatment for unfavorable prostate cancer" 09/01/2001 - "CONCLUSION: The excellent long-term results presented here, as well as the many advantages of prostate brachytherapy over other common treatments, demonstrate that brachytherapy is an effective treatment for clinical organ-confined prostate cancer in the long term." Order ALL the reference details at left...
4.	Castration 01/01/1990 - "As far as prostatic cancer is concerned, significant improvement occurs in the clinical conditions of patients affected by advanced neoplasia subjected to castration or oestrogen administration" 11/01/2004 - "Nonsteroidal antiandrogen monotherapy is as effective as castration in treatment of locally advanced prostate cancer offering quality of life benefits" 06/01/2004 - "BACKGROUND: Medical or surgical castration is effective in advanced prostate cancer but with profound side-effects, particularly on sexual function" 04/01/2004 - "It is estimated that in 2003, 220,900 new cases will be diagnosed and 28,900 men will die from the disease.1 Hormonal therapy via surgical or chemical castration is the mainstay of treatment for metastatic prostate cancer" 08/10/2001 - "CONCLUSION: Castration is effective for treatment of prostate cancer, especially among the elderly patients" Order ALL the reference details at left...
5.	Orchiectomy (Orchidectomy) 10/01/1997 - "We studied 30 adult males aged 40 to 70 years: 10 had had bilateral orchidectomy and/or maximal androgen blockade for > or = 6 months for treatment of prostate cancer, and all were in complete remission (group 1)" 05/01/1989 - "The clinical efficacy of high dose (160 mg) polyoestradiol phosphate (PEP) was compared with that of orchiectomy in a prospective randomised multicentre study including 200 prostatic cancer patients" 01/01/1990 - "Efficacy of orchiectomy versus high dose polyoestradiol phosphate (160 mg) in relieving infravesical obstruction in patients with prostatic cancer." 01/01/2005 - "Better designed testicular/prostate cancer studies have demonstrated that, while sexual desire is reduced by orchiectomy, the capacity to develop an erection in response to sexually stimulating material is not eliminated" 12/15/1993 - "Total androgen blockade is a more effective treatment for metastatic prostate cancer than orchiectomy alone in this study population." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Prostatic Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1551 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>